SynaptixBio develops targeted gene therapies for severe leukodystrophies, utilizing advanced vector delivery systems to facilitate precise genetic modifications. The company addresses the critical need for effective treatments in a group of rare, debilitating disorders that lead to progressive neurological decline.
Funding
$16.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Leukodystrophies are a group of rare, inherited disorders that cause progressive degeneration of the white matter in the brain, leading to severe neurological disabilities and reduced life expectancy. Effective treatments are lacking for most forms of leukodystrophy, creating a critical unmet need for patients and their families.
Solution
SynaptixBio is developing gene therapies that target the underlying genetic causes of severe leukodystrophies. Their approach utilizes advanced adeno-associated virus (AAV) vector delivery systems to precisely deliver therapeutic genes to affected cells in the brain. By correcting the genetic defects, SynaptixBio aims to halt or reverse the progression of these debilitating disorders and improve patient outcomes.
Target Audience
The primary target audience includes patients diagnosed with specific severe leukodystrophies and their families, as well as physicians specializing in neurology and genetic disorders.
Features
- AAV vector-based gene therapy platform for targeted delivery of therapeutic genes
- Focus on addressing the genetic mutations responsible for specific leukodystrophy subtypes
- Development of therapies designed to restore white matter function and prevent further neurological decline